Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Voltage-gated sodium channels (Nav1) are essential transmembrane proteins that mediate the rapid influx of sodium ions across the cell membrane, a process fundamental to the initiation and propagation of action potentials in excitable tissues [6, 9]. The Nav1 family comprises nine distinct alpha-subunit isoforms (Nav1.1 through Nav1.9), which are expressed in a tissue-specific manner across the central and peripheral nervous systems, as well as in skeletal and cardiac muscle [7, 13]. These channels play a pivotal role in physiological processes such as sensory perception, motor control, and cardiac rhythmicity [5, 12]. Dysregulation or mutations in the genes encoding these subunits (SCN1A-SCN11A) are associated with a wide spectrum of diseases, known as channelopathies, including various forms of epilepsy, chronic pain syndromes, and life-threatening cardiac arrhythmias [5, 9]. Pharmacologically, Nav1 channels are targeted by a diverse array of drugs, including local anesthetics, antiarrhythmics, and anticonvulsants, which typically function by blocking the ion-conducting pore in a state-dependent manner [7, 8]. Recent evidence also suggests that Nav1 channels are expressed in non-excitable cells, such as cancer cells, where they may contribute to invasive and metastatic behavior [1, 10]. The structural complexity of these channels, involving four homologous domains and auxiliary beta subunits, allows for fine-tuned regulation of electrical signaling [6, 11]. Therapeutic development continues to focus on subtype-selective inhibitors to minimize off-target effects, particularly for the treatment of chronic pain and epilepsy [2, 8].
Drugs targeting Nav1 channels typically act through state-dependent blockade of the ion-conducting pore [13]. They primarily bind to a conserved receptor site located in the S6 segment of domain IV, which stabilizes the channel in its non-conducting inactivated state, thereby inhibiting the influx of sodium ions and preventing membrane depolarization [7, 9].
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-gated sodium channel (Nav1) (Nav1).